Introduction
Metal-on-metal (MoM) hip resurfacing arthroplasty (HRA) is an alternative to conventional total hip arthroplasty (THA) and was developed as a more conservative procedure for younger patients in an effort to delay the need for conventional THA (1) . The cited advantages of HRA over THA include preservation of femoral bone stock, the ability to resume impact activity, lower dislocation rates, a reduction in stress shielding and less complex revision surgery (2) (3) (4) (5) (6) . HRA first became popular in the 1970s but during the 1980s fell out of favour due to high complication and failure rates (7) (8) (9) (10) . Second generation HRA was introduced in to the UK in the late 1990s following improvements in surgical technique, implant design and bearing surface (1, 11) . This renaissance in HRA however, has not been without complications. Specific designs have suffered early failure (12) (13) (14) (15) and there is concern regarding Hunter et al 51 expectations and clinical judgement. All procedures were carried out in a laminar air-flow theatre and utilised a posterior approach to the hip joint. Patients were all mobilised fully weight bearing postoperatively and were discharged once medically fit and able to mobilise independently.
Patients were followed up at 6 weeks, 12 weeks, 1 year and then every 5 years. All patients underwent functional scoring using the Oxford Hip Score (OHS) (24) preoperatively and at follow-up. Anteroposterior (AP) and lateral radiographs were obtained at follow-up. Metal ion levels were not routinely measured. Any complications were recorded and failure was defined as revision for any reason.
Statistical analysis was undertaken using the R statistical package (R Foundation for Statistical Computing). Analysis of differences in functional scores was performed using paired student t-tests and Kaplan-Meier curve was used to illustrate survivorship. A p-value of <0.05 was considered statistically significant.
Results
Between January 2004 and December 2005 129 patients had 139 BHRs performed. Primary osteoarthritis (OA) was the most common diagnosis (86%), followed by inflammatory arthropathy (3.6%), developmental hip dysplasia (2.9%), avascular necrosis (<50% of the femoral head) (2.9%), slipped capital femoral epiphysis (2.2%) and Perthes disease (1.4%). 18 patients had been lost at the latest follow-up, leaving 121 BHRs in 111 patients. Of the 18 patients lost to follow-up 8 had died (all with the implant in situ). 70 patients (63%) were male and 41 were female and the mean age at time of surgery was 52.5 years (53.9 for males and 48.8 for females). The mean head size was 52 mm in the male group and 46 mm in the female group. All patients had a minimum follow-up time of 10 years. There were 11 revisions giving an overall survivorship of 91% (Fig. 1) . 1 prosthesis was revised for a femoral neck fracture, another for infection and the remaining 9 revisions were for pain and/or loosening. In the female group the survivorship was 80% and in the male group it was 97% (Fig. 2) . There was a statistically significant difference between preoperative and postoperative OHS (p = <0.01) and no statistically significant difference between initial postoperative scores and the latest scores. The majority of failures had a head size of 46 mm or less (64%) but this difference was not found to be statistically significant.
Discussion
MoM HRA was reintroduced with numerous cited advantages over conventional THR, particularly for younger patients. These included preserved femoral bone stock and an ability to resume high impact activities with low risk of dislocation (25) . Many HRA devices were marketed and a large amount of results data exists in national registries (18, 26) . Since its peak in the mid 2000s, concerns over ALVAL and pseudotumour formation, along with the withdrawal and subsequent litigation involving certain implants, has seen a drastic fall in the number of HRAs performed.
Despite this, the BHR has been shown to be performing well when compared with other HRA devices. 10-year survival has shown to be 91.2% and 93.1% in the English and Australian registries respectively (18, 26) . Individual series have also demonstrated good results. Treacy et al (20) report 95.5% survival whilst Daniel et al (6) report 97.4% survival. There are also non-designer series that have shown similar results (21, 22) . Results are comparable to that of conventional THA in patients of a similar age. In our series the overall 10-year survival was 91% and this is comparable to the results in the NJR. In the male population the survival was 97% whilst in females it was found to be 80%. It has been well documented that females suffer worse outcomes in HRA than men, particularly with smaller head sizes (27, 28) . This was echoed in our series with a substantially worse implant survivorship in female patients than in men. We also observed that smaller 10-year results of the Birmingham Hip resurfacing 52 head sizes were more likely to be revised but this result was not statistically significant.
When considering functional outcomes, we saw a statistically significant improvement in OHS (p = <0.01) from before and after surgery and there was no significant difference in score in subsequent follow-up, indicating that that the functional benefit of the BHR is still present at 10 years follow-up. Interestingly, we found no statistical difference in postoperative scores between the male and female groups at the most recent follow-up, suggesting that although there is a much higher failure rate in females, functionally the outcome is comparable to that of the male group in patients that still have the implant.
The senior author no longer uses the BHR in female patients due to high failure rate and the widespread literature showing poor outcomes in this group. Our study has shown that using a well-established design such as the BHR and provided care is taken with patient selection, excellent long-term results can be achieved with MoM HRA and the results are comparable to conventional THA in patients of a similar age.
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